doubleinactiv
candid
whole
viru
vaccin
sever
acut
respiratori
syndrom
associ
coronaviru
sarscov
develop
manufactur
larg
scale
use
ferment
cultur
serum
protein
free
vero
cell
two
step
inactiv
procedur
involv
sequenti
formaldehyd
uv
inactiv
utilis
order
ensur
extrem
high
safeti
margin
respect
residu
infect
immunogen
doubleinactiv
vaccin
characteris
mous
model
mice
immunis
twice
candid
sarscov
vaccin
develop
high
antibodi
titr
sarscov
spike
protein
high
level
neutralis
antibodi
use
adjuv
al
oh
minor
effect
immunogen
vaccin
addit
cell
mediat
immun
measur
stimul
elicit
vaccin
moreov
vaccin
confer
protect
immun
demonstr
prevent
sarscov
replic
respiratori
tract
mice
intranas
challeng
sarscov
protect
mice
correl
antibodi
titr
sarscov
protein
neutralis
antibodi
titr
sever
acut
respiratori
syndrom
new
diseas
emerg
china
late
spread
rapidli
around
world
epidem
result
infect
almost
death
rais
consider
concern
emerg
agent
constitut
seriou
threat
global
public
health
identif
novel
coronaviru
sarscov
associ
syndrom
human
thu
despit
disappear
diseas
human
still
urgent
need
rapid
develop
safe
effect
vaccin
gener
consid
live
attenu
virus
effect
viral
vaccin
abil
induc
strong
cellular
humor
immun
respons
howev
need
extens
safeti
test
vaccin
delay
entri
candid
vaccin
clinic
trial
multipl
studi
report
antibodi
direct
spike
glycoprotein
neutralis
sarscov
infect
protein
report
bind
human
angiotensin
convert
protein
mediat
viral
entri
cell
human
monoclon
antibodi
direct
protein
report
reduc
replic
viru
lung
infect
ferret
complet
prevent
develop
sar
cov
induc
lung
patholog
addit
number
candid
vaccin
induc
protect
challeng
live
viru
anim
model
protect
associ
high
level
neutralis
antibodi
thu
like
inactiv
recombin
candid
vaccin
contain
protein
abl
induc
protect
immun
base
primarili
stimul
humor
immun
respons
favour
develop
inactiv
candid
whole
viru
vaccin
wellestablish
technolog
rapid
develop
vaccin
previous
report
use
larg
scale
vero
cell
ferment
cultur
develop
inactiv
whole
viru
influenza
vaccin
technolog
adapt
develop
doubl
inactiv
whole
viru
sar
cov
candid
vaccin
report
characteris
candid
vaccin
respect
safeti
immunogen
sarscov
cdc
also
refer
strain
utah
genbank
access
number
obtain
cdc
atlanta
usa
isol
sputum
sar
patient
usa
specimen
passag
two
time
gmp
grade
vero
cell
denatur
sampl
purifi
sarscov
vaccin
g
proteinlan
separ
trishcl
sodium
dodecyl
sulfatepolyacrylamid
gel
reduc
condit
subsequ
blot
onto
pvdf
membran
protein
stain
done
aurody
tm
fort
stain
kit
amersham
bioscienceg
healthcar
uk
accord
manufactur
instruct
rabbit
antibodi
direct
sarscov
nucleocapsid
n
protein
protein
respect
obtain
imgenex
san
diego
ca
usa
use
western
blot
analysi
block
applic
primari
antibodi
overnight
c
work
dilut
membran
wash
incub
h
room
temperatur
hors
radish
peroxidas
hrp
label
goat
antirabbit
igg
accur
chemic
westburi
usa
follow
final
wash
blot
develop
use
diaminobenzidin
tetrahydrochlorid
h
femal
mice
week
old
obtain
charl
river
laboratori
subsidiari
sulzfeld
germani
sampl
preimmun
sera
mice
immunis
six
differ
dose
candid
vaccin
rang
g
ng
total
protein
method
accord
bradford
evalu
effect
adjuvant
immunogen
vaccin
nonadjuv
prepar
materi
adjuv
aluminium
hydroxid
alum
test
antigen
concentr
group
mice
inocul
subcutan
sc
ml
vaccin
prepar
control
group
receiv
volum
buffer
trisbuff
salin
without
aluminium
hydroxid
fourteen
day
postimmunis
sera
drawn
anim
booster
immunis
carri
formul
dosag
inocul
primari
immunis
sera
drawn
anim
week
primari
immunis
anim
treat
aluminium
hydroxid
contain
vaccin
also
bled
week
primari
immunis
balbc
mice
week
old
also
obtain
charl
river
laboratori
subsidiari
cytokin
studi
group
mice
balbc
mice
immunis
sc
g
vaccin
adjuv
alum
booster
inject
formul
given
day
post
primari
immunis
mice
sacrif
cervic
disloc
day
primari
immunis
five
mice
per
group
singl
cell
suspens
prepar
pool
spleen
five
anim
forc
minc
tissu
mesh
stainless
steel
siev
red
blood
cell
deplet
incub
min
room
temperatur
lysi
buffer
contain
nh
cl
mm
khco
na
edta
ph
leukocyt
suspend
complet
cell
cultur
medium
subset
immunis
mice
ie
four
mice
group
receiv
vaccin
dose
ng
control
group
see
section
challeng
week
group
receiv
nonadjuv
aluminium
hydroxid
contain
prepar
week
aluminium
hydroxid
primari
immunis
prior
challeng
blood
sampl
drawn
determin
neutralis
antibodi
titr
challeng
mice
anaesthetis
isofluran
inocul
intranas
dose
tcid
sarscov
contain
volum
l
l
per
nostril
nonclon
sarscov
cdc
propag
five
time
serum
protein
free
vero
sf
cell
use
homolog
challeng
day
post
inocul
pi
mice
euthanis
isofluran
follow
barbitur
lung
trachea
remov
frozen
c
prior
titrat
tcid
assay
tissu
sampl
thaw
homogenis
ml
vero
cell
cultur
medium
supplement
antibiot
igg
titr
protein
sarscov
determin
indirect
elisa
briefli
microtit
plate
coat
overnight
c
ng
baculoviru
bv
express
fulllength
histag
protein
protein
scienc
meriden
ct
usa
mm
carbon
buffer
ph
per
well
left
uncoat
respect
subsequ
wash
block
h
nonfat
dri
milk
serial
fourfold
dilut
sera
start
dilut
appli
h
room
temperatur
follow
three
wash
phosphatebuff
salin
pb
contain
tween
bound
antibodi
detect
hrplabel
goat
antimous
igg
accur
chemic
westburi
ny
usa
work
dilut
follow
wash
develop
use
opdh
final
colour
develop
stop
addit
h
plate
read
nm
elisa
plate
reader
biotek
winooski
vt
usa
determin
endpoint
antibodi
titr
absorb
read
equal
greater
cutoff
valu
four
time
mean
absorb
valu
dilut
neg
control
serum
consid
posit
serum
sampl
serial
dilut
cell
cultur
medium
twofold
step
usual
begin
dilut
serum
dilut
mix
ratio
viru
stock
suspens
adjust
tcid
ml
incub
h
room
temperatur
transfer
eight
replic
per
dilut
tissu
cultur
plate
seed
vero
cell
plate
incub
day
c
co
incub
cultur
inspect
light
microscop
presenc
cytopath
effect
cpe
caus
sarscov
ie
cell
round
detach
neutralis
titr
calcul
number
viru
neg
well
serum
dilut
accord
method
spearman
frequenc
secret
cell
analys
use
mous
elispot
kit
mabtech
ab
nacka
sweden
follow
instruct
manufactur
serial
dilut
freshli
isol
spleen
cell
balbc
mice
ad
well
rang
cell
per
well
antibodyco
plate
stimul
sar
candid
vaccin
recombin
bvexpress
protein
ad
concentr
gml
well
contain
antigen
gml
pokewe
mitogen
sigma
st
loui
usa
use
neg
posit
control
respect
plate
incub
overnight
c
co
cell
discard
plate
wash
pb
respect
detect
biotinyl
specif
antibodi
follow
streptavidinalkalin
phosphatas
develop
bcipnbt
substrat
solut
number
spot
count
use
autom
elispot
reader
aid
strassberg
germani
number
spot
observ
well
contain
antigen
subtract
number
spot
observ
well
contain
specif
antigen
result
express
spot
form
cell
sfc
per
spleen
cell
infecti
viru
titr
sarscovcontain
sampl
determin
tcid
assay
brief
serial
dilut
viru
contain
sampl
inocul
onto
microtit
plate
seed
vero
cell
incub
day
c
co
incub
plate
screen
light
microscop
presenc
cpe
number
viru
posit
well
per
dilut
tcid
calcul
accord
poisson
formula
mean
inhous
calcul
softwar
program
program
provid
estim
tcid
titr
confid
limit
base
onehit
model
previous
report
develop
formalin
inactiv
whole
viru
influenza
vaccin
produc
use
largescal
serum
protein
free
vero
cell
ferment
cultur
develop
candid
sarscov
vaccin
base
adapt
well
establish
technolog
establish
optim
condit
growth
inactiv
purif
inactiv
viru
sarscov
report
grow
well
vero
cell
consid
probabl
optim
cell
matrix
rapid
vaccin
develop
primari
viru
seed
gener
human
isol
five
sequenti
plaqu
clone
primari
seed
amplifi
gener
seed
viru
bank
work
viru
bank
product
viru
bank
product
viru
use
infect
serum
protein
free
cultur
use
ferment
volum
l
follow
incub
period
day
viru
contain
supernat
harvest
inactiv
formalin
treatment
h
follow
uv
inactiv
uv
dose
mjcm
viru
infect
multipl
infect
moi
result
gener
high
viral
titr
tcid
ml
supernat
formalin
uv
inactiv
step
independ
capabl
inactiv
titr
larg
margin
safeti
manuscript
prepar
follow
inactiv
viru
subject
twostep
purif
involv
continu
flow
zonal
centrifug
sucros
gradient
follow
ultradiafiltr
process
result
twostep
purif
procedur
demonstr
fig
two
lot
purifi
vaccin
subject
western
blot
analysi
stain
specif
anti
glycoprotein
fig
antin
antibodi
fig
addit
protein
composit
analys
stain
colloid
gold
fig
figur
demonstr
final
purifi
bulk
vaccin
pure
contain
protein
n
protein
band
equival
molecular
weight
infecti
viru
particl
prior
inactiv
purif
crosslink
protein
also
seen
inactiv
prepar
electron
micrograph
purifi
inactiv
prepar
confirm
data
fig
viru
particl
demonstr
present
well
defin
spike
viru
membran
immunogen
candid
vaccin
initi
investig
dosefind
adjuv
studi
perform
mice
purpos
group
mice
immunis
twice
decreas
dose
purifi
nonadjuv
adjuv
vaccin
dose
rang
g
ng
evalu
effect
adjuvant
immunogen
vaccin
nonadjuv
prepar
materi
adjuv
aluminium
hydroxid
test
antigen
concentr
specif
antibodi
titr
neutralis
antibodi
titr
individu
serum
determin
describ
section
geometr
mean
titr
gmt
determin
group
anim
present
fig
data
demonstr
candid
vaccin
highli
immunogen
mice
follow
singl
immunis
g
specif
antibodi
titr
gmt
approxim
adjuv
formul
nonadjuv
formul
measur
week
primari
immunis
data
shown
neutralis
antibodi
titr
measur
time
point
follow
booster
immunis
elisa
titr
substanti
increas
gmt
could
obtain
g
dosag
adjuv
aluminium
hydroxid
reduct
dosag
littl
ng
adjuv
formul
still
result
develop
low
titr
antibodi
respons
fig
high
titr
neutralis
antibodi
approxim
also
measur
g
adjuv
nonadjuv
formul
week
booster
immunis
fig
group
mice
immunis
aluminium
hydroxid
formul
bled
week
booster
immunis
demonstr
high
titr
specif
neutralis
antibodi
still
detect
stage
fig
influenc
adjuv
specif
antibodi
respons
also
determin
calcul
effect
dose
ed
ie
minimum
amount
antigen
requir
seroconvers
mice
two
immunis
data
tabl
demonstr
follow
booster
immunis
nonadjuv
vaccin
contain
alum
induc
similar
antibodi
respons
ed
valu
ng
respect
obtain
nonadjuv
adjuv
alum
vaccin
vaccin
adjuv
alum
somewhat
immunogen
seventi
percent
mice
develop
specif
antibodi
protein
even
lowest
dose
appli
ie
ng
due
high
proport
seroconvert
ed
could
exactli
calcul
fig
sspecif
neutralis
antibodi
respons
sarscov
vaccin
mice
booster
immunis
sspecif
antibodi
titr
week
c
respect
determin
elisa
neutralis
antibodi
respons
mice
week
b
week
respect
analys
micro
neutralis
assay
geometr
mean
titr
group
receiv
nonadjuv
vaccin
grey
bar
vaccin
adjuv
black
bar
aluminium
hydroxid
open
bar
present
n
antibodi
titr
n
neutralis
titr
neutralis
antibodi
detect
due
limit
amount
serum
instanc
detect
limit
assay
ng
proport
anim
demonstr
neutralis
antibodi
titr
also
analys
subset
immunis
mice
n
ed
base
neutralis
antibodi
respons
also
calcul
tabl
data
similar
obtain
elisa
igg
determin
differ
somewhat
highest
proport
anim
neutralis
antibodi
seen
adjuv
formul
highest
concentr
alum
characteris
immun
respons
mice
carri
investig
specif
cytokin
respons
vaccin
type
immun
respons
determin
measur
marker
respons
marker
respons
cytokin
studi
balbc
mice
immunis
sc
g
antigen
adjuv
alum
booster
inject
formul
given
day
post
primari
immunis
mice
sacrif
day
primari
immunis
spleen
cell
isol
balbc
mice
stimul
purifi
recombin
protein
candid
vaccin
see
section
data
present
fig
show
substanti
respons
obtain
two
immunis
whole
viru
vaccin
howev
respons
whole
viru
vaccin
substanti
higher
obtain
follow
stimul
recombin
protein
two
immunis
follow
third
immunis
respons
recombin
protein
increas
level
obtain
whole
viru
antigen
wherea
signific
respons
could
still
detect
upon
stimul
recombin
protein
addit
could
demonstr
littl
gml
whole
viru
antigen
suffici
stimul
substanti
respons
follow
demonstr
candid
vaccin
highli
immunogen
protect
efficaci
vaccin
investig
mice
subset
ie
four
mice
per
group
mice
immunis
dosefind
adjuv
studi
see
challeng
week
post
primari
immunis
intranas
deliveri
tcid
homolog
viru
strain
viru
replic
respiratori
tract
monitor
describ
section
data
present
tabl
demonstr
nonadjuv
vaccin
vaccin
prepar
adjuv
aluminium
hydroxid
highli
effect
induc
specif
anti
antibodi
neutralis
antibodi
antigen
dose
low
ng
without
adjuv
effect
induc
neutralis
antibodi
immunis
anim
respect
challeng
tcid
live
viru
result
viru
replic
lung
mock
immunis
mice
howev
immunis
candid
vaccin
antigen
dose
low
ng
result
high
degre
protect
vaccin
mice
anim
protect
reduc
dose
antigen
still
result
partial
protect
immunis
mice
protect
follow
immunis
ng
vaccin
antigen
similar
data
obtain
vaccin
prepar
adjuv
aluminium
hydroxid
data
shown
protect
dose
pd
calcul
three
vaccin
formul
shown
approxim
equal
pd
ng
calcul
formul
without
adjuv
alum
alum
respect
tabl
data
present
tabl
indic
clear
correl
specif
igg
titr
protein
pi
post
inocul
sspecif
antibodi
titr
measur
elisa
neutralis
antibodi
titr
nt
micro
neutralis
assay
sarscov
titr
homogenis
lungtrachea
tissu
determin
tcid
assay
given
log
tcid
g
lung
tissu
neutralis
antibodi
titr
protect
intranas
challeng
live
viru
data
confirm
summaris
protect
data
obtain
mous
model
tabl
summaris
data
obtain
total
mice
use
variou
immunis
studi
cours
develop
data
tabl
demonstr
specif
anti
igg
titr
result
protect
mice
challeng
tcid
live
viru
also
demonstr
specif
neutralis
titr
result
protect
challeng
tabl
viru
replic
seen
mice
antibodi
titr
level
contrast
control
anim
infect
intranas
challeng
tcid
live
viru
report
describ
extens
immunolog
characteris
candid
sar
coronaviru
vaccin
number
differ
strategi
previous
report
develop
experiment
candid
human
sar
vaccin
includ
inactiv
whole
viru
vaccin
attenu
viral
vector
express
sarscov
protein
dna
vaccin
favour
strategi
whole
viru
vaccin
develop
number
reason
includ
speed
develop
viru
grow
high
titr
vero
cell
cell
line
accept
regulatori
author
similar
technolog
use
develop
utilis
develop
industri
scale
product
influenza
viru
vaccin
manufactur
facil
also
place
appropri
biosafeti
level
utilis
technolog
rapid
larg
scale
vaccin
product
howev
addit
technolog
logist
reason
also
like
inactiv
whole
viru
vaccin
would
effici
induc
neutralis
antibodi
possibl
critic
prevent
sarscov
infect
process
inactiv
whole
viru
vaccin
utilis
either
formaldehyd
inactiv
agent
report
inactiv
failur
associ
methodolog
even
recent
past
therefor
develop
strategi
involv
doubl
inactiv
process
utilis
formaldehyd
uv
inactiv
although
formaldehyd
report
react
protein
nucleic
acid
reaction
nucleic
acid
particularli
nucleic
acid
compon
viru
particl
less
well
establish
therefor
decid
introduc
second
inactiv
step
addit
formaldehyd
ie
uv
inactiv
direct
primarili
nucleic
acid
process
independ
demonstr
capabl
inactiv
tcid
ml
larg
margin
safeti
manuscript
prepar
howev
also
essenti
demonstr
combin
inactiv
step
destroy
viral
antigen
structur
immunogen
data
present
fig
demonstr
major
viru
antigen
ie
glycoprotein
n
protein
neg
effect
addit
breakdown
product
could
detect
compar
noninactiv
prepar
addit
transmiss
electron
microscopi
analysi
uranyl
acet
stain
sampl
demonstr
inactiv
virion
present
welldefin
spike
structur
viru
particl
appar
structur
alter
result
inactiv
procedur
antigen
structur
analys
follow
extens
immunolog
characteris
candid
vaccin
dose
find
adjuv
studi
carri
mice
measur
antibodi
respons
specif
elisa
infect
neutralis
titr
data
present
fig
demonstr
doubl
inactiv
prepar
highli
immunogen
specif
elisa
titr
obtain
follow
two
immunis
g
antigen
adjuv
aluminum
hydroxid
high
neutralis
titr
also
obtain
follow
immunis
booster
g
antigen
titr
approxim
obtain
immunogen
appear
higher
report
whole
viru
vaccin
subject
singl
inactiv
step
although
differ
methodolog
make
direct
comparison
difficult
doubl
inactiv
vaccin
also
abl
induc
high
antibodi
respons
even
absenc
adjuv
similar
data
report
uv
inactiv
vaccin
inactiv
vaccin
littl
differ
level
neutralis
antibodi
mice
report
minim
influenc
adjuvant
vaccin
immunogen
also
confirm
studi
calcul
ed
littl
differ
ed
nonadjuv
alum
adjuv
materi
although
alum
adjuv
materi
appear
immunogen
tabl
howev
confirm
ed
calcul
basi
neutralis
antibodi
respons
nonadjuv
materi
immunogen
prepar
alum
tabl
addit
characteris
humor
respons
antibodi
measur
respons
immunis
analys
cytokin
product
data
present
fig
demonstr
doubl
inactiv
candid
vaccin
capabl
induc
cytokin
marker
respons
howev
respons
stimul
recombin
protein
indic
cell
respons
protein
predominantli
respons
would
expect
alum
adjuv
whole
viru
vaccin
agreement
data
report
immunis
uvinactiv
sarscov
demonstr
substanti
respons
immunis
follow
demonstr
immunogen
vaccin
investig
initi
demonstr
efficaci
candid
vaccin
prevent
infect
small
anim
model
balbc
mice
establish
good
rodent
model
replic
sar
cov
demonstr
viru
replic
well
respiratori
tract
mice
model
use
investig
protect
efficaci
vaccin
data
tabl
demonstr
adjuv
nonadjuv
vaccin
prepar
antigen
concentr
g
protect
immunis
mice
challeng
high
titr
tcid
viru
intranas
rout
vaccin
appear
effect
low
dose
antigen
calcul
pd
tabl
nonadjuv
adjuv
vaccin
confirm
low
antigen
concentr
approxim
ng
suffici
provid
protect
immunis
mice
figur
even
lower
calcul
highli
effect
wellestablish
flaviviru
vaccin
tickborn
enceph
calcul
pd
ng
similar
model
unpublish
data
protect
studi
also
use
establish
serolog
correl
protect
data
tabl
demonstr
induct
neutralis
antibodi
titr
specif
elisa
titr
result
protect
intranas
challeng
tcid
infecti
viru
data
clearli
indic
doubl
inactiv
whole
viru
vaccin
promis
candid
effect
human
vaccin
use
two
inactiv
step
base
differ
mechan
infect
ensur
safeti
respect
residu
infecti
viru
howev
report
vaccin
felin
coronaviru
vaccin
result
antibodi
induc
enhanc
infect
suggest
phenomenon
could
induc
challeng
studi
report
studi
protect
achiev
induct
neutralis
antibodi
mva
parainfluenza
vector
spike
protein
live
viral
vaccin
howev
vaccin
induc
enhanc
coronaviru
infect
requir
studi
report
vaccin
ferret
rmva
express
sarscov
protein
associ
enhanc
hepat
